Last reviewed · How we verify
NCT03896971
Combination of Thrombopoietin Mimetic and Immunosuppressive Therapy in Aplastic Anaemia
Phase 4 trial testing Combination of thrombopoietin mimetic and cyclosporin A in Aplastic Anemia in 66 participants. Completed in 1 June 2021.
1 December 2020
Quick facts
| Lead sponsor | Safaa AA Khaled |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 66 |
| Start date | 15 November 2019 |
| Primary completion | 1 December 2020 |
| Estimated completion | 1 June 2021 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Combination of thrombopoietin mimetic and cyclosporin A — full drug profile →
Conditions studied
- Aplastic Anemia — all drugs for Aplastic Anemia →
Sponsor
Safaa AA Khaled — full company profile →
Who can join
Adults 16 to 65, any sex, with Aplastic Anemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To the investigator's Knowledge this is the first study that will assess Treatment with thrombopoietin Mimetic plus immunosuppressiveTherapy in Egyptian Patients with Aplastic Anaemia. Aim of the work : 1. To evaluate the efficacy, tolerability and toxicity of the combination of thrombopoietin mimetic and immunosuppressive therapy in Egyptian patients with AA. 2. To study the influence of this combination on patients' quality of life. 3. To access evolution to paroxysmal nocturnal hemoglobinuria (PNH), myelodysplastic syndrome , acute leukemia or development of fibrosis
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03896971
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Aplastic Anemia
Currently open trials in the same condition.
- NCT07101770 — A Prediction Model in Pregnant Women With Aplastic Anemia · recruiting
- NCT06752694 — Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult P · Phase 2 · recruiting
- NCT06936930 — Reproductive and Mental Health of Patients With Aplastic Anemia · recruiting
- NCT06689800 — Let's Get REAL: Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy · NA · recruiting
- NCT06613880 — Standard Immunosuppressive Therapy Combined With Romiplostim N01 as First-line Treatment for Severe Aplastic Anemia · Phase 2 · recruiting
Other Safaa AA Khaled trials
Trials by the same sponsor.
- NCT04312607 — Value of CD26 Positive Leukemic Stem Cell in Myeloproliferative Neoplasm · unknown
- NCT04106323 — A Study of Factor Inhibitors in Adult Patients With Hemophilia and Von Willebrand's Disease in Upper Egypt · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03896971 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Safaa AA Khaled
- Last refreshed: 29 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03896971.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing